<div id="readability-page-1"><div id="block-content"> Amgen’s bispecific T-cell engager tarlatamab received regulatory approval in China, marking an important expansion for the company’s oncology portfolio into one of the world’s largest cancer markets.The approval, granted by China’s National Medical Products Administration and announced by development and commercialization partner BeOne Medicines, covers adult patients with extensive-stage small cell lung cancer whose disease has progressed following chemotherapy, an area of significant unmet need.1Marketed in the United States as Imdelltra, tarlatamab is designed to target delta-like ligand 3 on tumor cells and CD3 on T cells, effectively redirecting the immune system to attack cancer.2The therapy is part of Amgen’s broader strategy to advance bispecific antibodies, a class of immunotherapies that has gained traction for its ability to engage immune cells more precisely than traditional approaches. Imdelltra received from FDA back in 2024.When FDA approved Imdelltra, Jay Bradner, M.D., executive vice president, Research and Development, at Amgen not the importance, &#34;The FDA's decision reinforces Imdelltra as a recognized standard of care for people living with extensive stage small cell lung cancer whose disease progressed on or after frontline therapy. We are committed to delivering transformative medicines for patients facing challenging cancers, and we are currently focused on rapidly developing Imdelltra in earlier stages of disease and earlier lines of therapy for small cell lung cancer patients.&#34;Clinical data supporting the approval highlights the therapy’s potential in a difficult-to-treat population. In the Phase II DeLLphi-301 study, tarlatamab demonstrated an objective response rate of 46.3% among previously treated patients, with a median duration of response of 7.2 months.3Median progression-free survival was 5.4 months, while overall survival reached 19.0 months, suggesting a meaningful clinical benefit in a setting where treatment options remain limited.Safety findings were also consistent with expectations for this class of therapy, with cytokine release syndrome beiing the most commonly reported adverse event, occurring in 48.8% of patients, though all cases were grade 1 or 2, and no patients discontinued treatment due to therapy-related side effects.3 These results indicate a manageable safety profile alongside durable responses, a combination that could support broader adoption in clinical practice.Despite the approval, key commercial details, including launch timing and pricing in China, have not been disclosed.1 Neither Amgen nor BeOne Medicines responded to requests for additional information. However, analysts have pointed to strong market potential, with some estimating that Tarlatamab could generate more than $2 billion in annual sales globally if uptake meets expectations.1China’s approval of Tarlatamab reflects a growing emphasis among multinational drugmakers on expanding access to innovative cancer therapies in international markets, particularly in Asia, where incidence rates for lung cancer remain high.For Amgen, the decision also reinforces the strategic importance of partnerships in navigating regional regulatory and commercialization pathways.<ol><li>Amgen's lung cancer drug tarlatamab wins China approval Reuters April 10, 2026 </li><li>FDA Grants Full Approval to Amgen’s Indelltra In Extensive Stage Small Cell Lung Cancer Amgen November 19, 2025 </li><li>Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer National Library of Medicine September 4, 2025 .</li></ol> </div></div>

688235

06160

AMGN

Amgen's bispecific T-cell engager tarlatamab has received regulatory approval in China, expanding its oncology portfolio into a major cancer market. The approval, announced by BeOne Medicines, is for adult patients with extensive-stage small cell lung cancer who have progressed after chemotherapy. Tarlatamab, marketed as Imdelltra in the U.S., targets specific proteins on tumor cells and T cells to enhance immune response. Clinical data shows a 46.3% objective response rate and manageable safety profile. Commercial details remain undisclosed, but analysts predict significant market potential, estimating over $2 billion in annual sales globally.

<![CDATA[Amgen’s Tarlatamab Approved in China ]]>